766
Participants
Start Date
June 1, 2025
Primary Completion Date
July 1, 2027
Study Completion Date
March 1, 2028
Intensive lipid-lowering strategy
The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin plus Ezetimibe or PCSK9i, and the type and dosage of drugs can be adjusted according to the situation. If the target LDL-C level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
Standard lipid-lowering strategy
The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin, and the type and dosage of drugs can be adjusted according to the situation. If the target L-DLC level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
The First Affiliated Hospital of Dalian Medical University, Dalian
The First Affiliated Hospital of Chongqing Medical University, Chongqing
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou
Guangdong Provincial People's Hospital, Guangzhou
The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen
The Ninth Clinical Medical College of Guangzhou University of Chinese Medicine, Dongguan
Zhongshan People's Hospital, Zhongshan
Liu yong
OTHER